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Available online 2 June 2013Abstract The clinical application of human bone marrow stromal cells (hBMSCs) largely depends on their capacity to expand
in vitro. We have conducted a comprehensive comparative proteomic analysis of culture-expanded hBMSCs obtained from
different human donors. The data reveal extensive donor-to-donor proteomic heterogeneity. Processing and database-
searching of the tandem MS data resulted in a most comprehensive to date proteomic dataset for hBMSC. A total of 7753
proteins including 712 transcription and translation regulators, 384 kinases, 248 receptor proteins, and 29 cytokines were
confidently identified. The proteins identified are mainly nuclear (43.2%) and the share of proteins assigned to more than one
subcellular location constitutes 10% of the identified proteome. Bioinformatics tools (IPA, DAVID, and PANTHER) were used to
annotate proteins with respect to cellular locations, functions, and other physicochemical characteristics. We also compared
the proteomic profile of hBMSCs to recently compiled datasets for human and mouse pluripotent stem cells. The result shows
the extent of similarity between the three cell populations and also identified 253 proteins expressed uniformly by all lines of
hBMSCs but not reported in the proteomic datasets of the two pluripotent stem cells. Overall, the proteomic database reported
in this paper can serve as a reference map for extensive evaluation of hBMSC to explain their biology as well as identify possible
marker candidates for further evaluation.
Published by Elsevier B.V.Introduction
Mesenchymal stromal cells were originally described as
stromal cells from bone marrow in the hematopoietic
microenvironment that formed adherent colonies when⁎ Corresponding author. Fax: +1 301 827 0449.
E-mail address: Michail.Alterman@fda.hhs.gov (M.A. Alterman).
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http://dx.doi.org/10.1016/j.scr.2013.05.006cultured ex vivo and demonstrate osteogenic potential
(Friedenstein et al., 1968, 1970; Sensebe et al., 2010).
Since their first description, cells with similar characteristics
have been derived from numerous tissues including cord
blood, adipose tissue, cartilage, dental pulp, and muscle
(Kuhn and Tuan, 2010). The cells obtained from bone
marrow were named mesenchymal stem cells in 1991 by
Caplan (Caplan, 1991). In 2005, the International Society for
Cellular Therapy (ISCT) recommended the term multipotent
Table 1 HBMSC lines and donor characteristics. Cells from
two commercial sources were obtained at P1 and a proteomic
comparison was performed at P3, P5, and P7.
Donor # Cell line Sex Age Cell source Race
1 PCBM1641 F 23 All Cells Hispanic
2 167696 F 22 Lonza Hispanic
3 PCBM1632 M 24 All Cells Black
4 110877 M 22 Lonza Black
5 8F3560 F 24 Lonza Hispanic
6 PCBM1662 F 31 All Cells Caucasian
794 S.T. Mindaye et al.mesenchymal stromal cells to be used to refer to fibroblast-
like cells with a set of properties including plastic-
adherence, in vitro trilineage differentiation capacity, and
expression of a defined set of cell-surface antigens (Dominici
et al., 2006; Horwitz et al., 2005). The ISCT's definition has
been widely adopted although recent evidence has shown
that the characteristics of stromal cells vary depending on
their tissue sources. Moreover, the true multipotency and
self-renewing capacity of stromal cells from various tissues
have not been confirmed with rigorous bioassays (Bianco et
al., 2013). A particular challenge to the field has been the
absence of the unique set of markers that can be used to
enrich MSCs from other connective tissue cell populations
and define them functionally. There is much discussion of
the functional definition, nomenclature, and experimental
handling of multipotent stem cells as can be observed in
recent reviews (Bianco et al., 2010, 2013; Keating, 2012). In
this paper the term bone marrow stromal cells (BMSCs) is
used to refer to plastic adhering bone marrow-derived
colonies of stromal progenitors that express a set of cell-
surface phenotypes defined by ISCT. Such cells have been
referred to by various names in the literature including
mesenchymal stem/stromal cells (MSCs).
While stem cell-based therapies hold great potential for
the treatment of a wide array of medical conditions they are
so novel that product characterization is particularly chal-
lenging. Despite considerable progress, the molecular regu-
latory mechanisms of self-renewal and lineage specification
in these cell types are largely unexplored. In recent years a
number of “omics” technologies were applied to investigate
MSCs (Jansen et al., 2010; Kulterer et al., 2007; Ng et al.,
2008; Ren et al., 2011). The majority of earlier proteomic
studies were performed by a combination of two dimensional
electrophoresis (2DE) and matrix assisted laser desorption
ionization mass spectrometry (MALDI MS). The first proteomic
investigation reported by Colter et al. resulted in the
identification of 40 differentially regulated proteins between
rapidly self-renewing and mature human BMSCs (hBMSCs)
(Colter et al., 2001). Similar techniques were used to study
the effect of transforming growth factor beta (TGF-β) (Wang
et al., 2004), shear stress (Yi et al., 2010), and mechanical
strain and TGF-β (Kurpinski et al., 2009), or disease
conditions such as rheumatoid arthritis (Kastrinaki et al.,
2008), osteoarthritis (Rollin et al., 2008), and idiopathic
scoliosis (Zhuang et al., 2011) on hBMSCs. Other studies used
combinations of 2DE and MALDI MS to compare the proteomic
variability between MSCs isolated from various sources
such as amniotic fluid, bone marrow, umbilical cord,
placenta, adipose tissue, and synovial membrane (Roche et
al., 2009).
However, the well-documented poor performance of 2DE
with regard to membrane, basic, and low abundance
proteins limited the exploration of such complex biological
samples as MSCs (Chevalier, 2008). Recent trends show
that on-line multi-dimensional liquid chromatography (LC)
coupled with MS significantly improves proteomic coverage.
This approach dramatically increased the number of proteins
identified (~900) including hundreds of membrane proteins
from hBMSCs (Niehage et al., 2011). On the other hand,
off-line 2D-LC fractionation followed by MALDI MS was also
applied successfully to study the proteomic architecture of
distinct populations of hBMSC (Mareddy et al., 2009).The number of proteins identified to date in hBMSC
(b1000) clearly indicates that we have only scratched the
surface of the proteome and detected mainly abundantly
and moderately expressed proteins. A deeper molecular
analysis of the proteome, transcriptome, and protein
interactome of hBMSCs would lead to a better understanding
of these cells. An additional difficulty is the absence of a
unified analytical approach which makes the comparison of
data obtained in different laboratories challenging, partic-
ularly in combination with the well-documented heteroge-
neity of hBMSCs.
In this study we applied a combined proteomic approach
that included pressure cycling-based protein harvesting, 3D
fractionation, and complementary MS strategies (electrospray
ionization (ESI) and MALDI) to improve proteomic character-
ization of culture-expanded hBMSCs obtained from different
human donors. We created the largest proteomic database for
hBMSCs reported to date. The results obtained highlight the
surprisingly large degree of proteomic variability in hBMSC
cell lines obtained from six human donors. Furthermore,
results of extensive bioinformatic analyses of relevant
molecular events, biological processes, signaling pathways,
and protein–protein interaction networks (interactome) that
are operating in these cell populations are also presented and
discussed.Materials and methods
Cell cultures
HBMSC lines from six human donors (four females and two
males, Table 1) were obtained from commercial sources. Cell
lines PCBM1641, PCBM1632, and PCBM1662 were obtained at
passage 1 (P1) from All Cells. Lines 167696, 110877, and
8F3560 were purchased from Lonza at P1. All donors fulfilled
institutional requirements at the time of cell collection.
According to the manufacturers, following informed consent
bone marrow aspirates were taken and plastic adherent
hBMSCs were harvested. The time of culture prior to harvest
was 15, 15, and 14 days for cell lines 167696 (at 90%
confluence), 110877 (at 45% confluence), and 8F3560 (at
35% confluence). At this stage cells were designated as P0 by
the supplier. Cells were further cultured to P1 for 6, 6, and
7 days, respectively, collected at 95% confluence, and
frozen. Cell lines PCBM1641, PCBM1632, and PCBM1662 were
795Global proteomic signature of human bone marrow stromal cellsin culture to 80% confluence for 14, 15, and 20 days,
respectively before collection at P1.
P1 cells from Lonza met commonly used specifications for
hBMSC cell surface markers (≥90% positive for CD29, CD44,
CD105, and CD166; ≤10% positive for CD14, CD34, and
CD45). Extensive characterization and authentication of
hBMSC lines from All Cells was performed as described by Lo
Surdo and Bauer for PCBM1641 and PCBM1632 (Lo Surdo and
Bauer, 2012). In regard to the expression of surface markers
the cell lines were at least 90% positive for CD73, CD90,
CD105, CD29, CD44, and CD166, and less than 5% positive for
CD45, CD34, CD14, CD79α, and HLA-DR. The characteriza-
tion in terms of colony forming unit assay and adipogenic
differentiation potential was performed. All cell lines
included in this study met commonly used specifications for
hBMSCs (Dominici et al., 2006; Horwitz et al., 2005).
For our experiments, P1 cells were plated at a density of
60 cells/cm2 density in T175 flasks (Cellstar), culture-expanded
in α-MEM (Invitrogen) supplemented with 16.5% fetal bovine
serum (FBS) (JM Bioscience, San Diego, CA), L-glutamine and
penicillin–streptomycin (Pen/strep) (Invitrogen), and cul-
tured at 37 °C and 5% CO2 as described by Lo Surdo and
Bauer (2012). A passage number is the number of times cells
were trypsinized prior to freezing. The time to P3, P5, and P7
was calculated: PCBM1641 (7, 8, and 8 days, respectively),
167696 (8, 10, and 12 days), PCBM1632 (7, 9, and 17 days),
110877 (8, 9, and 10 days), 8F3560 (9, 10, 9 days), and
PCBM1662 (10, 9, and 12 days). The cell lines vary in their
proliferation capacity, which generally decreases with pas-
saging. The full proliferation kinetic characterization for
PCBM1641 and PCBM1632 was described by Lo Surdo and
Bauer (2012), while the growth profile characterization of
167696 and 110877 was given elsewhere (Mindaye et al.,
2013). At 80% confluence, cells were harvested using 0.25%
Trypsin/EDTA (Invitrogen), washed using phosphate buffered
saline three times, snap frozen in liquid nitrogen, and stored
at −80 °C at 5 × 106 cells at passages 3 (P3), 5 (P5), and 7 (P7)
for later use. The same serum lotwas used for the expansion of
all cell lines to 3 passages.Proteome preparation, MS analyses, data processing,
and bioinformatic analyses
The detailed protocol for sample preparation, LC/MALDI MS,
LC-ESI MS, and LC-ESI (MSE), analyses, data processing and
database searching, and additional bioinformatic analyses are
provided in Supplement 1. For MALDI MS analysis lysates from
all cell lines were electrophoretically resolved into six
fractions using the GELFREE system that allowed continuous
separation of proteins through a gel-packed tube. Eluting
proteins are trapped by a molecular weight cut off membrane
and subsequently collected in solution phase, which was
suitable for downstream MS analysis. From 200 μg of total
protein, six fractions were collected (Supplement 1). Based
on polyacrylamide gel electrophoresis data the first fraction
was estimated to contain ~40% of the total protein loaded and
all subsequent five fractions each had ~12% (data not shown).
Fractionated samples were subjected to trypsin digestion
followed by RP HPLC using an offline MALDI MS analysis.
Triplicate analysis of samples from each cell line (at P3, P5,
and P7) required a total of 54 LC injections. Each injectionwas collected into 372 fractions (spots) on a MALDI target
plate so that the total fractions collected from the six
cell lines equaled 120,528 (54 × 372 × 6). Subsequently,
1,228,000 tandem MS spectra were collected. All fragment
spectra from triplicate runs of each line were combined and
an inChorus database search was launched using PEAKS
Studio software (Perkins et al., 1999; Zhang et al., 2012).
Mascot search results, namely, peptide and protein lists,
were exported in Excel format. Then, all DTA files generated
were combined and used for further filtering based on false
discovery rate (FDR) using Scaffold software (http://www.
proteomesoftware.com/). Confident protein identification
considered a set of filter criteria including identification
scores, overall probability, and FDR. Furthermore, proteins
were identified using multiple peptides (90% of the proteome)
and the majority of the identifications were done with at least
1 unique peptide.
For ESI-based MS analysis, cell lysates from PCBM1641,
167696, and PCBM1632 cells were fractionated using the
GELFREE system and digests were prepared as described in
Supplement 1. The digest from PCBM1641 was analyzed with
the LTQ MS after 1D chromatographic peptide separation.
The tandem MS experiment results were used for SwissProt
database search. The digests from 167696 and PCBM1632
were analyzed using a Synapt G2 QTof MS. Tryptic peptides
in this case were separated using 2D nanoAcquity UPLC
(Supplement 1). Following MSE acquisition, the data were
processed using PLGS software (Li et al., 2009) and queried
against target as well as one-time randomized human
database (SwissProt). In contrast, the cell lysates from
lines 110877, 8F3560, and PCBM1662 were digested without
prior GELFREE protein fractionation steps and analyzed using
a Synapt G2 QTof MS after 2D nanoAcquity UPLC peptide
separation. In this case, instead of protein fractionation,
which significantly adds to the overall analysis time, the
number of fractions in the first dimension separation was
increased to 13 prior to the second dimension separation
(Supplement 1).Results
Cell culturing and protein identification
Proteomic analyses of hBMSCs obtained from six donors were
performed by a comprehensive approach developed in our
laboratory (Mindaye et al., 2013). This approach includes
pressure-assisted protein extraction, GELFREE protein frac-
tionation, and multidimensional chromatographic peptide
separation with subsequent complimentary ionization tech-
nique MS analysis for improved protein identification.
Proteomic analyses were performed using 5 × 106 cells.
Based on the stringent criteria, a total of 6192 proteins at a
FDR of 0.8% were identified from six cell lines using MALDI MS
data. The protein identification summary from each cell line
is given in Table S1 (Supplement 2) and the list of proteins
identified using MALDI MS is provided in Table S2. ESI-based
proteome characterization was also performed either after
GELFREE fractionation of the cell lysate (for PCBM1641,
167696, and PCBM1632) or without intact protein fraction-
ation (cell lines 110877, 8F3560, and PCBM1662). The
summary of proteins identified using ESI technique is
796 S.T. Mindaye et al.provided in Table S1 (Supplement 2) and the list of proteins
is provided in Table S3 (Supplement 2).
Overall, data acquired using ESI MS led to the identifica-
tion of 8828 proteins from six cell lines with 3866 of them
being non-redundant (Supplement 2, Table S3). Similarly,
from MALDI MS data a sum of 21,013 proteins was recovered,
where 6192 were identified as non-redundant (Supplement
2, Table S2). Thus, the total number of proteins identified in
this study using the two complimentary MS techniques was
29,841. As shown in Fig. 1A, only a third of the non-
redundant proteins (31%) were identified using both ESI MS
and MALDI MS datasets. Apparently, MALDI MS identified
more proteins than ESI MS (82% of the total proteome as
compared to 51% for ESI MS). Similar observations have also
been reported from other proteomic studies, where MALDI
MS increases the number of additional protein identifica-
tions from complex biological samples by an average of 45%
(Yang et al., 2007), which is close to the improvementFigure 1 A summary of the proteomic characterization of hBMSCs.
Only 30% of the total proteins identified from hBMSCs were identified
the isoelectric point distribution of proteins of hBMSCs identified u
weight distribution of proteins identified from hBMSCs using LC-E
distribution of proteins identified from six hBMSC lines. Shown on the
number of cell lines.achieved in this study (52%). Overall, the total number of
non-redundant proteins identified from six cell lines was
7753 (Supplement 2, Tables S1).
The physicochemical properties of proteins from ESI MS
and MALDI MS datasets were compared and summarized as
shown in Figs. 1B–D. The proteins were mapped in relation
to their theoretical molecular weight (Mw) and isoelectric
point (pI), which were calculated with the help of Compute
pI/Mw tool (www.expasy.org). The predicted pI distributions
from the two datasets (MALDI vs. ESI) follow similar trends of
bimodality centered at around pI 5 and 9, and these peaks
are separated by a trough at around pI 7.5. Consistent with
data on other cell types, the proteome of hBMSCs shows the
characteristic trend and that most proteins have evolved to
partition away from the close to neutral cytosolic pH, at
which proteins are generally less soluble (Weiller et al.,
2004). The trough consists mostly of proteins of nuclear
origin. This trimodal distribution is characteristic of thePanel A compares proteins identified using ESI MS and MALDI MS.
using the two MS techniques. Panels B and C, respectively, show
sing LC/MALDI MS and LC-ESI MS. Panel D reveals the molecular
SI MS and LC/MALDI MS. Revealed in Panel E is the frequency
histogram is the cumulative number of proteins expressed by≥n
797Global proteomic signature of human bone marrow stromal cellseukaryotic proteome. In both cases, the peak on the acidic
side rises sharply and is more abundant (62% and 56% for ESI
MS and MALDI MS, respectively) than the one on the alkaline
side.
Expression overlap between cell lines: the proteomic
basis of donor-to-donor variability
One of the challenges facing clinical use of MSCs is the
differences in biological activities between cells obtained
from different donors (Pevsner-Fischer et al., 2011; Phinney,
2007, 2012). The qualitative and/or quantitative variability of
the cell proteome and the posttranslational modifications are
likely the most significant contributor to this functional
heterogeneity. We attempted to evaluate the extent of
protein expression variability in cell lines obtained from
different donors. Fig. 1E summarizes the frequency of protein
identification. From the total proteins, approximately one
out of six (1353 proteins) was identified from one cell line but
not from the others, and only 13% (1024 proteins) were
identified from all cell lines (Table S4, Supplement 2). This
fraction included proteins critical for major biological
functions in MSCs. For example, leukemic inhibitory factor 2
(LIF2) is implicated in the maintenance of stemness in MSCs
(Kolf et al., 2007). Beta-catenin, a component of the
canonical Wnt signaling pathway, is also important for MSC
self-renewal (Kolf et al., 2007; Ling et al., 2009). Also,
serine/threonine–protein kinase (DCLK3) regulates a number
of transcription factors and determines MSC fate through its
positive effectors of the non-canonical Wnt signaling pathway
(Ling et al., 2009). Likewise, other important transcription
factors such as RAS-responsive element binding protein 1,
HMG box transcription factors (e.g., nuclear transcription
factor 1), and basic helix–loop–helix transcription factors
(e.g., aryl hydrocarbon receptor nuclear transcription factor
2) have also been found to be expressed uniformly between
cell lines.
Proteins expressed in at least 50% of the cell lines
accounted for 62% of the total proteome identified, while
the number increases to 79% (6113 proteins) if expression is
evaluated from two or more cell lines (Supplement 2, Table
S2 and S3).
Sub-cellular localization of proteins
Proteins perform biological functions within the context of
their spatial time-resolved localization in a living cell.
Generally, the ultimate localization of proteins can be
determined by the amino acid sequences because some of
these sequences are recognized by specific location-receptor
proteins (Imai and Nakai, 2010). This principle, together with
other features such as protein sorting signals, sequence
homology with a protein of known localization, and protein–
protein interaction data, is used in subcellular prediction
algorithms. The subcellular localization of hBMSC proteins
was classified using the ngLOC web-based server from the
University of Nebraska Medical Center (http://ngloc.unmc.
edu/) (King and Guda, 2007). ngLOC is a Bayesian method for
predicting sub-cellular localization of proteins at proteome
scale. The method relies on the density distribution of fixed
length peptide sequences (n-gram) derived from the primarystructure of proteins. It can classify proteins into at least 10
distinct subcellular localizations including cytoplasm, endo-
plasmic reticulum, extracellular/secreted, golgi, lysosomes,
mitochondria, nucleus, junction, peroxysomes, and plasma
membrane. Furthermore, it can also infer the localization of
proteins if they appear at more than one site.
A summary of the subcellular localization of the hBMSC
proteome is given in Figs. 2A and B. Fig. 2A represents
proteins that are predicted to localize at a unique
subcellular location (90% of the total proteome); the
majority of them are nuclear (43.2%), followed by cytoplas-
mic (17.6%), and then plasma membrane proteins (13.6%).
Of the total proteome, 10% were predicted to appear at
more than one location and Fig. 2B describes their
distribution. The existence of proteins at multiple locations
is a widely appreciated phenomenon (Zhang et al., 2008).
Such proteins, which may account for as much as 35% of the
total proteome, may simultaneously be located within or
undergoing transport between different cellular compart-
ments (Zhang et al., 2008). Not surprisingly, the majority
(47%) of such proteins reside at the cytoplasm/nucleus site.
Examples include pergerin, a component of the MOZ/MORF
complex, which has a transcription regulation role (Ullah et
al., 2008); endothelial differentiation-related factor 1,
which is another transcription regulator that can be involved
in cell differentiation (Dragoni et al., 1998); and cystatin-B,
which is a reversible inhibitor of cathepsins L, H, and B.
Moreover, proteasome activator complex subunit 3, a
subunit of the 11S REG-gamma proteosome regulator,
resides in the cytoplasm during mitosis following nuclear
envelope breakdown (Brooks et al., 2000). Proteins residing
at cytoplasm/plasma membrane site are the second most
abundant in the class (10%) followed by those at cytoplasm/
cytoskeleton (8%).Major biological processes, pathways, and protein–
protein interaction networks in hBMSCs
Most large-scale functional studies rely on resources provid-
ed by the Gene Ontology (GO) Consortium. GO annotations
can be accessed from major biological databases such as
UniProt, Ensembl, EntrezGene, and others (Barrell et al.,
2009). We used the publicly available PANTHER server to do
functional classification of the hBMSC proteome (Thomas et
al., 2003). PANTHER (Protein ANalysis THrough Evolutionary
Relationships) allows browsing of a manually curated data-
base by functions, where the database was established using
published evidence as well as evolutionary relationships.
The accuracy of protein function prediction was estimated
using statistical models (Hidden Markov Models, HMMs)
constructed for each functional protein group (Thomas et
al., 2003).
The UniProt accession numbers of hBMSC proteins were
used to search in the PANTHER database. The search results
were displayed as summaries of molecular function, biological
process, cellular compartment, protein class, and pathway
enrichment using the input proteomic dataset (Fig. 3). The
y-axis shows the number of genes related to a particular
biological process shown on the x-axis. Evidently, culture-
expanded hBMSCs were metabolically active. In addition to
the primary metabolic processes (carbohydrate, protein,
Figure 2 Predicted sub-cellular localization of the proteome of hBMSCs (n = 7753 proteins). Shown in A is the profile of proteins
predicted to reside at one cellular location, while shown in B is the profile for proteins expected to be present at two locations. The
notations are as follows: CYT (cytoplasm), EXC (extracellular), NUC (nuclear), PLA (plasma membrane), GOL (golgi), END
(endoplasmatic), LYS (lysosome), CSK (cytoskeleton), JNC (junction), MIT (mitochondria), POX (peroxisome). Annotation was
performed using ngLOC program.
798 S.T. Mindaye et al.lipid, amino acid, and nucleotide metabolism), specialized
processes including coenzyme metabolism, ferredoxin and
porphyrin metabolism, and vitamin metabolism have been
enriched. Proteins that are involved in various cellular
processes including cell adhesion, chromosome segregation,
cell communication, cell motion, and cytokinesis were also
identified. Proteins involved in mitotic proliferation of
hBMSCs are represented by 112 proteins. Members of the
caspase family (e.g., caspase 2), cyclins and cyclin-dependent
kinases (CDKs) have been identified and these proteins are
known to influence cell number through their involvement in
mitosis and apoptotic events (Malumbres, 2011; Zhu et al.,
2006). The immunomodulatory role of MSCs has been one of
the capacities explored for potential application in cell
therapy (Chen et al., 2011). HBMSCs express both pro- and
anti-inflammatory proteins and the proteome is enriched
with proteins involved in immune response through antigen
processing and presentation (e.g., cathepsins), cellular
activation (e.g., retinoic acid and tumor necrosis factors)
and various other chemokines and cytokines. In contrast to
the markedmolecular variability described above (only 13% of
the proteome overlaps), the overall profile of biological
processes demonstrated remarkable similarity (Fig. 3). The
same pattern was observed when the proteomes were
screened based on signaling pathways (data not shown). Thisphenomenon may be partly explained by the fact that cellular
functions could be carried out by different but functionally
similar proteins (Omelchenko et al., 2010).
For lack of a reference proteome for culture-expanded
hBMSCs we assembled one by using proteins expressed from
at least 50% of cell lines (three out of six). The reference
proteomic map (4797 proteins, Supplement 2, Table S5) was
used to enrich molecular events representative of hBMSCs.
Accordingly, the reference proteome, which was mapped
into 4645 genes in the PANTHER database, helped to enrich
5098 molecular functions, 8309 biological processes, and
2252 pathways potentially operating in hBMSCs. As an
example, the classification based on signaling pathways is
summarized in Fig. 4. As shown, integrin signaling is the most
enriched pathway with 120 genes associated with it. The
integrins are transmembrane receptors and are involved
primarily in sensing the extracellular matrix environment.
Their binding with ligands from the extracellular environ-
ment leads to the activation of intracellular signaling events
that are essential in cell migration, growth and survival
(Danmark et al., 2012; Martin et al., 2002; Parsons et al.,
2012). Chemokine and cytokine signaling pathways related
to inflammation are enriched by 105 genes. Also, hBMSCs
express a wide array of chemokines and cytokines, which
together with their receptors, play important roles in
























801Global proteomic signature of human bone marrow stromal cellshoming, migration, and engraftment of cells to the inflam-
mation sites (Docheva et al., 2008). The Wnt signaling
pathway, which has a vital role in developmental regulation
and cell fate determination (Etheridge et al., 2004; Ling et
al., 2009), was enriched with 98 genes. Excessive activation
of beta-catenin-dependent Wnt signaling leads to activated
DNA damage followed by increased senescence and reduces
proliferation of MSCs (Zhang et al., 2011). Wnt signaling
molecules have also been shown to inhibit early stages of
adipogenesis (Laudes, 2011). Represented by 40 genes is the
p53 pathway, which plays a role in the differentiation
(Molchadsky et al., 2008) and aging of MSCs (Zhang et al.,
2011). Other major signaling pathways include cytoskeletal
regulation by Rho GTPase (68 genes), angiogenesis (65
genes), and cadherin signaling (46 genes). Growth factor
signaling pathways have also been enriched: EGF receptor-
mediated (58 genes), FGF (49 genes), PDGF (56 genes), VEGF
(33 genes), and TGF-β (25 genes). These have been reported
to be involved in developmental regulation of MSCs through
differentiation (Ng et al., 2008), migration (Veevers-Lowe et
al., 2011), and self-renewal (Coutu and Galipeau, 2011;
Rodrigues et al., 2010).
Proteins rarely act alone; to exert their functions
efficiently they interact with each other. To see major
relationships between proteins of hBMSCs, we performed
protein–protein interaction network analysis using the Inge-
nuity Pathway Analysis (IPA) software. The accession numbers
in the reference proteome (4797 proteins, Supplement 2,
Table S5) were uploaded and 4713 of the proteins (98%) found
matches in the IPA knowledge base (IPAKB). A Core Analysis
was run to enrich interaction networks. The analysis
considered only direct interaction relationships, which have
been confirmed experimentally or predicted with high
confidence. According to the IPA, direct interaction exists
when there is evidence that proteins interact physically with
one another. Networks were ranked based on their score,
which is the negative log of their p-value. The scoring takes
into account the number of eligible molecules, the size of the
network, and the total number of molecules known to be
associated with that network in IPAKB. The information in the
IPAKB is curated manually and is composed from published
literature and major external databases. The list of top 25
high scoring interaction networks according to our screening
is presented in Supplement 3.
A general interactome scheme between molecules in the
top-ranking networks was built by merging 7 relevant
networks (Supplement 4, Fig. S1). The interactome map is
represented graphically by 648 nodes (molecules) and 3127
edges (biological relationships between nodes) with an
edge-to-node ratio exceeding 4.8, which means that the
interactions in the network are highly unlikely to be random
events. As the general interactome illustrates there are a
number of biologically relevant interaction networks that
are good candidates for further examination to generate a
testable hypothesis or for an in-depth scientific scrutiny in
regard to their importance in hBMSC biology. Nevertheless,
even though the direct interaction relationships revealed in
the general interactome model are supported by literature
evidence from IPAKB, it needs to be reminded that not all of
them have been proven experimentally, and interpretation
of these modeled interactions needs to be treated with
caution.Comparison between proteomes of hBMSCs and
pluripotent stem cells (PSCs)
The proteomes of human and mouse pluripotent stem cells
(hPSCs and mPSCs) that were recently compiled accounted
for a total of 7487 and 7295 proteins, respectively (Gundry
et al., 2011). We compared the proteome set compiled in
this study for hBMSCs against the datasets for hPSCs and
mPSCs. For the analysis, the accession numbers of proteins
were uploaded onto the IPA software and parsed using the
“Compare data” option of the software to output proteins
shared between the three cell types. The screening shows
that the proteomes of the three distinct cell populations
share at least 2479 proteins between them (Supplement 4,
Fig. S3). The overlapping proteins encompass a network of at
least 152 transcription regulators, 971 binding proteins, 911
proteins with catalytic properties, 89 receptors, ion chan-
nels, and transporters. The unique part of the hBMSCs
proteome accounted for 28% (2789 proteins). Furthermore,
the comparative map of CDs expressed on the three cell
types is presented in Table S7 (Supplement 2). The
comparison involves 116 hBMSC CDs, 102 hPSCs CDs, and
111 mPSCs CDs and revealed that the three cell types
expressed at least 41 CDs in common.
Discussion
The current consensus is that not many proteins are
expressed in a cell-specific manner. In fact, it has been
reported that less than 1% of the human proteome is
expressed in either single or a few cell types (Gry et al.,
2010). This epitomizes the huge challenge that has to be
overcome during the identification of protein markers that
correlate with specific biological or clinical outcomes.
Human BMSCs are poorly characterized in part because of
the lack of comprehensive molecular evaluation. Therefore,
the data presented in this report, in addition to its
correlation with complex biological and molecular networks
operating in hBMSCs, serves as a reference proteomic
database for comparative work to identify and evaluate
possible marker candidates for hBMSCs. The data obtained in
this study also provide insight into donor-to-donor MSC
proteome heterogeneity.
Previous proteomic studies on hBMSCs had limited
proteomic coverage and reported only the most abundant
proteins. In contrast, this report is based on a total of 7753
proteins, which encompasses 712 transcription and transla-
tion regulators including SOX-9, -11, -13, -15, -18, and -30.
The expression of SOX-2 and OCT-4, which are factors for
pluripotency maintenance, was not detected (Pierantozzi et
al., 2011). The expression of Stro-1 could not be detected,
which is consistent with previous reports showing that the
expression of Stro-1 ceases with cell culture expansion (Kolf
et al., 2007). Many members of the STAT family (signal
transducer and activator transcription) including STAT-1, -3,
-4, 5A, -5B, and -6 have also been identified in this study.
STAT proteins are responsible for multiple cellular activities
including the regulation of growth, survival, differentiation,
motility, and immune response (Akira, 1999). The proteomic
data also revealed the expression of 384 kinases (e.g., MAP
kinases, PAKs, and CDKs), 248 receptors (e.g., TLR-2, -4, -6,
802 S.T. Mindaye et al.-7, and -9), and 29 cytokines (e.g., chemokines, interleu-
kins, and tumor necrosis factors).
The donor-to-donor proteomic variability documented in
this paper can help to explain previous reports that show
functional discordance between cell populations from
different donors (Phinney, 2007, 2012). As per our data,
only 13% of the total proteins were found universally
expressed by all cell lines. Such a high degree of molecular
diversity is a little surprising given the fact that samples
from all cell lines were treated under similar conditions. The
cell lines used in this studywere obtained from two commercial
sources (Materials and Methods section) and the cell-handling
protocols during isolation from bone marrow aspirates could
have contributed to the proteomic heterogeneity. To
examine the existence of such affect, we compared the
proteomic datasets compiled using cell lines from All Cells
(n = 3) and Lonza (n = 3). In total, 6327 and 7015 proteins
were identified from All Cells and Lonza, respectively. The
two datasets shared at least 5596 proteins between them
(72% similarity) and evidently the variability between the
two group-proteomic datasets is not typically higher than
the variability calculated for proteomes from individual
donors (Table 2). The reference proteome we constructed
based on this study (Supplement 2, Table S5) is not
differentially represented by any proteomes of the two
commercial cell sources (respectively, 97% and 99% of the
proteins in the reference proteome were identified from
hBMSCs obtained from All Cells and Lonza). Furthermore,
hBMSCs from the two sources have also been compared in
terms of growth kinetics, differentiation capacity, and cell
surface markers. Although functional differences can be
observed, none of these can be associated with the cell
source or can be observed in different patterns of cell
surface marker expression. Overall, functional and proteo-
mic variabilities which have been observed between cell
lines in this study cannot be linked directly to commercial
cell source.
Molecular and functional heterogeneities in cell popula-
tions is not unique to hBMSCs; it is a widespread phenom-
enon among stem cells including embryonic (Canham et al.,
2010), hematopoietic (Schroeder, 2010), neural (Suslov et
al., 2002), and cancer stem cells (Wong et al., 2012). The
analysis of major proteomic studies (n = 34) of human and
mouse pluripotent stem cells (hPSCs and mPSCs) by Gundry
et al. highlighted the degree of heterogeneity among
pluripotent stem cell populations (Gundry et al., 2011).Table 2 Summary of protein expression variability between






PCBM1641 2768 2434 28.4
167696 5667 4444 8.7
PCBM1632 4225 3615 21.8
110877 4404 3639 22.2
8F3650 4716 3961 17.1
PCBM1662 4395 3431 26.0
Ref proteome is a reference proteome for hBMSCs constructed
arbitrarily by taking proteins expressed in at least three of the
six human cell lines.According to their analysis, the comparison of nine major
human proteomic studies, which together indexed 6966
proteins, revealed that less than 20% of the proteins were
identified from at least 50% of the studies. By comparison,
our proteomic screening from six cell lines found 62% of the
proteins to be shared by at least 50% of the study subjects.
The better proteomic overlap achieved in our study does not
necessarily mean that hBMSCs are less heterogeneous than
hPSCs. Rather, it reflects uniformity in the analytical
proteomic approach.
The comparison between the hBMSC proteomic dataset
with pluripotent stem cells revealed that numerous proteins
are commonly expressed between the three cell types. It
also has revealed that 28% (2879) of the hBMSC proteins were
not identified from the PSC types. However, not all of these
proteins were uniformly expressed between cell lines, only
253 have been identified in all six lines (Supplement 2, Table
S6). While hBMSCs, hPSCs, and mPSCs expressed at least 41
CDs in common, 39 CDs have been identified exclusively
from the hBMSC dataset. Only 15 CDs out of these 39 were
identified from at least three of the six hBMSC lines, and only
CD351 was identified from all lines. The 15 CDs are mostly
receptors (CD5L, CD11D, CD59, CD23, CD85D, CD108, CD123,
CD206, CD204, CD247, CD264, and CD351,) and some of
them are involved in calcium ion binding (CD437), or are
kinases (e.g., CD167, CDw293).
The reference proteomic map for hBMSCs, which was
constructed by combining proteins identified from at least
50% of cell lines, was used as a tool to get a quantitative
sense of the proteomic variability between cell lines. For
example, cell line 8F3560 has a proteome set of 4716
proteins, of which 3961 were also found in the reference
proteome and the remaining proteins (834) were not part of
the 8F3560 proteome. To account for the variability caused
by the size of a proteome we used a correction factor, which
is the ratio between the proteome size of a given cell line
and the reference proteome (in this case 4716/4797 = 0.98).
The reference proteome consists of 4797 proteins (Supple-
ment 2, Table S5). Thus, the percent variability will be 17.1%
(834/4795 * 0.98). Overall, an average variability between
lines was 20.9% (Table 2). We also screened the data to
determine if highly variably-expressed proteins are uniform-
ly distributed among cellular organelles. For this purpose,
the subcellular localizations of the most variably expressed
proteins (those expressed in ≤2 cell lines) were compared
against the profile obtained using the reference proteome
(Supplement 4, Fig. S2). There was no apparent bias towards
certain organelles in molecular variability between cell
lines, although the plasma membrane and mitochondria
contain slightly higher proportions of variably-expressed
proteins.
Previously, the donor-to-donor heterogeneity in MSCs has
been revealed through significant differences in growth rate
and clonogenic potential (Phinney et al., 1999). Such
inter-subject variabilities (donor-to-donor) have been con-
sidered to be caused for the most part by factors imposed by
long-term culture conditions (Bonab et al., 2006; Briquet et
al., 2010; Pevsner-Fischer et al., 2011; Schallmoser et al.,
2010; Lo Surdo and Bauer, 2012). However, intra-subject
heterogeneity (hBMSC population from the same donor)
has also been recognized and in fact it was proposed
that hBMSCs may actually exist in vivo as heterogeneous
803Global proteomic signature of human bone marrow stromal cellspopulations (Pevsner-Fischer et al., 2011; Phinney, 2007).
For example, only a restricted population of MSCs has been
shown to express neuroregulatory proteins (Crigler et al.,
2006), or demonstrate selective in vivo tumor-homing
properties (Bolontrade et al., 2012), or possess the capacity
to express interleukin 1 receptor antagonist (Ortiz et al.,
2007). Their plastic nature, the capacity to differentiate,
and the complex stroma in the bone marrow favor hBMSCs to
exist as heterogeneous subpopulations. In fact, such hetero-
geneity has a biological advantage in tissues, as it allows the
selection of the appropriate cell type for various demanding
conditions more so than a rigid and homogenous population
(Pevsner-Fischer et al., 2011).
Summary
We performed the largest proteomic analysis to date of
culture-expanded hBMSC obtained from different human
donors. Processing and database-searching of the tandem MS
data collected revealed a highly enlarged proteomic dataset
consisting of 7753 proteins. Bioinformatics tools including
IPA, DAVID, and PANTHER were used to annotate proteins
with respect to cellular locations, to analyze relevant
molecular events, signaling pathways, and protein–protein
interaction networks (interactome) that potentially influ-
ence MSC biology. Moreover, comparative analysis of the
data highlighted the surprising amount of proteomic hetero-
geneity between hBMSCs from 6 different donors. The
proteome of hBMSCs was compared with recently compiled
proteomes of mouse and human pluripotent stem cells. The
unique part of the hBMSC proteome has 253 proteins
identified in all cell lines. The three cell types expressed
41 CDs in common and 39 CDs were identified exclusively in
hBMSCs. Out of these 39 only CD351 was identified from all
cell lines. Overall, the results reported and the database
compiled in this study can serve as valuable resources in
further attempts to understand the complex biological and
molecular networks operating in hBMSCs and to identify
possible marker candidates for further evaluation.
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